Briacell Therapeutics Valuation
| BCTX Stock | USD 0.84 0.09 12.00% |
Today, the firm appears to be undervalued. Briacell Therapeutics shows a prevailing Real Value of $5.61 per share. The current price of the firm is $0.84. Our model approximates the value of Briacell Therapeutics from analyzing the firm fundamentals such as Current Valuation of 30.29 M, shares owned by insiders of 19.60 %, and Return On Equity of -2.06 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Briacell Therapeutics' valuation include:
Price Book 17.0305 | Enterprise Value 30.3 M | Enterprise Value Ebitda (1.38) |
Undervalued
Today
Please note that Briacell Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Briacell Therapeutics is based on 3 months time horizon. Increasing Briacell Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Briacell Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Briacell Stock. However, Briacell Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.84 | Real 5.61 | Target 20.0 | Hype 0.99 |
The intrinsic value of Briacell Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Briacell Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Briacell Therapeutics Corp helps investors to forecast how Briacell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Briacell Therapeutics more accurately as focusing exclusively on Briacell Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Briacell Therapeutics' intrinsic value based on its ongoing forecasts of Briacell Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Briacell Therapeutics' closest peers.
Briacell Therapeutics Cash |
|
Briacell Valuation Drivers Correlation
Many accounts on the financial statements of Briacell Therapeutics are highly interrelated and sometimes correlated. Consequently, when conducting Briacell's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Briacell
Click cells to compare fundamentals
Briacell Valuation Trend
Analysing the historical paterns of Briacell Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Briacell Therapeutics Corp over time and is usually enough for investors to make rational market timing decisions.
Briacell Therapeutics Total Value Analysis
Briacell Therapeutics Corp is currently anticipated to have valuation of 30.29 M with market capitalization of 31.15 M, debt of 8.56 M, and cash on hands of 41.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Briacell Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
30.29 M | 31.15 M | 8.56 M | 41.04 M |
Briacell Therapeutics Asset Utilization
One of the ways to look at asset utilization of Briacell is to check how much profit was generated for every dollar of assets it reports. Briacell Therapeutics Corp shows a negative utilization of assets of -1.26 percent, losing $0.0126 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Briacell Therapeutics Corp shows how discouraging it operates for each dollar spent on its assets.Briacell Therapeutics Ownership Allocation
Briacell Therapeutics holds a total of 36.18 Million outstanding shares. Briacell Therapeutics Corp shows 19.6 percent of its outstanding shares held by insiders and 12.88 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Briacell Therapeutics Profitability Analysis
Net Loss for the year was (4.93 M) with profit before overhead, payroll, taxes, and interest of 0.About Briacell Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Briacell Therapeutics. We calculate exposure to Briacell Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Briacell Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -82.6 K | -78.5 K |
Briacell Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.5 M |
Briacell Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Briacell Therapeutics Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Briacell we look at many different elements of the entity such as Briacell's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Briacell Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Briacell Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Briacell Therapeutics' worth.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.